RT Journal Article
T1 Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial.
A1 Paz-Ares, L
A1 Spira, A
A1 Raben, D
A1 Planchard, D
A1 Cho, B C
A1 Özgüroğlu, M
A1 Daniel, D
A1 Villegas, A
A1 Vicente, D
A1 Hui, R
A1 Murakami, S
A1 Spigel, D
A1 Senan, S
A1 Langer, C J
A1 Perez, B A
A1 Boothman, A-M
A1 Broadhurst, H
A1 Wadsworth, C
A1 Dennis, P A
A1 Antonia, S J
A1 Faivre-Finn, C
K1 PACIFIC
K1 PD-L1 expression
K1 durvalumab
K1 immunotherapy
K1 non-small-cell lung cancer
K1 stage III
AB In the PACIFIC trial, durvalumab significantly improved progression-free and overall survival (PFS/OS) versus placebo, with manageable safety, in unresectable, stage III non-small-cell lung cancer (NSCLC) patients without progression after chemoradiotherapy (CRT). We report exploratory analyses of outcomes by tumour cell (TC) programmed death-ligand 1 (PD-L1) expression. Patients were randomly assigned (2:1) to intravenous durvalumab 10 mg/kg every 2 weeks or placebo ≤12 months, stratified by age, sex, and smoking history, but not PD-L1 status. Where available, pre-CRT samples were tested for PD-L1 expression (immunohistochemistry) and scored at pre-specified (25%) and post hoc (1%) TC cut-offs. Treatment-effect hazard ratios (HRs) were estimated from unstratified Cox proportional hazards models (Kaplan-Meier-estimated medians). In total, 713 patients were randomly assigned, 709 of whom received at least 1 dose of study treatment durvalumab (n = 473) or placebo (n = 236). Some 451 (63%) were PD-L1-assessable: 35%, 65%, 67%, 33%, and 32% had TC ≥25%,  PFS benefit with durvalumab was observed across all subgroups, and OS benefit across all but TC
YR 2020
FD 2020-03-21
LK http://hdl.handle.net/10668/15280
UL http://hdl.handle.net/10668/15280
LA en
DS RISalud
RD Apr 6, 2025